The previously named “IDH—mutant secondary glioblastoma” has been reclassified as IDH—mutant Grade 4 astrocytoma, which has a survival rate at least two-fold higher than IDH—wildtype glioblastoma. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).